Nan Fung Life Sciences

About The Fund

Nan Fung Life Sciences, operating under the umbrella of the Nan Fung Group, is a global investment platform dedicated to the life sciences sector. The firm encapsulates a strategy that looks to partner with scientists, entrepreneurs, corporations, and investors, fostering a collaborative ecosystem in life sciences. Expanding its reach through Pivotal bioVenture Partners funds in both the United States and China, Nan Fung Life Sciences engages in direct investments, a strategy that has populated its portfolio with diverse assets across therapeutic, medical device, and diagnostic companies at various stages of development. Founded in 2017 and headquartered in Hong Kong, the organization maintains a substantial presence in both the U.S. and Greater China region. Through Pivotal bioVenture Partners, the firm invests in transformational therapeutic-focused healthcare companies across North America and Europe, very much embodying a venture capital role. In China, the focus shifts towards venture building in the life sciences, with strategic partnerships tailored around innovative healthcare companies. Furthermore, Pivotal Public Equity's operations concentrate on public equity, capturing investment opportunities among publicly traded life sciences entities poised for growth and scale. This multifaceted approach reflects Nan Fung Life Sciences' commitment to advancing high impact therapeutics and meeting significant medical needs. With a predefined investment bracket of approximately $70,190,000, the firm injects capital strategically into sectors such as Biotech, FinTech and Financial Services, HealthTech and Fitness, Medical Devices and Hospital Services, Healthcare and Wellness, Life Sciences, Oncology, and Pharmaceuticals and Medicine, showcasing its expansive domain expertise and adaptability to various subdivisions within the life sciences ecosystem.